KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Treasury Shares (2016 - 2025)

Pacira BioSciences has reported Treasury Shares over the past 15 years, most recently at $5.9 million for Q4 2025.

  • Quarterly results put Treasury Shares at $5.9 million for Q4 2025, up 609.09% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (up 609.09% YoY), and the annual figure for FY2025 was $5.9 million, up 609.09%.
  • Treasury Shares for Q4 2025 was $176.6 million at Pacira BioSciences, up from $125.5 million in the prior quarter.
  • Over the last five years, Treasury Shares for PCRX hit a ceiling of $5.9 million in Q4 2025 and a floor of $837000.0 in Q2 2024.
  • Median Treasury Shares over the past 5 years was $1.1 million (2022), compared with a mean of $1.7 million.
  • Peak annual rise in Treasury Shares hit 602.86% in 2025, while the deepest fall reached 200.61% in 2025.
  • Pacira BioSciences' Treasury Shares stood at $25.1 million in 2024, then soared by 602.86% to $176.6 million in 2025.
  • The last three reported values for Treasury Shares were $5.9 million (Q4 2025), $4.8 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.